Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2686303 | 0.91 | ABL1 (0.50) | TRPV1TRPM8SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2684532 | 0.89 | TRPV1 (0.46) | KCNQ3KCNQ2KCNE1KCNQ1POLB | |
| SCHEMBL2685801 | 0.89 | TRPV1 (0.56) | KCNQ3KCNQ2KCNE1KCNQ1TRPV1 | |
| SCHEMBL4060283 | 0.85 | KCNQ3 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1POLB | |
| SCHEMBL2685982 | 0.82 | TRPV1 (0.52) | TRPV1KIT | |
| SCHEMBL2686449 | 0.79 | TRPV1 (0.56) | TRPV1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2685401 | 0.79 | ABL1 (0.51) | TRPV1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2686002 | 0.78 | TRPV1 (0.54) | KCNQ3KCNQ2KCNE1KCNQ1TRPV1 | |
| SCHEMBL2687034 | 0.77 | MEN1 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1POLB | |
| SCHEMBL2684968 | 0.77 | ABL1 (0.54) | TRPV1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2012-05-10 | — | — | US | claimed |
| US-20100022523-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-01-28 | — | — | US | claimed |
| EP-1775283-A1 | 3-AMINOBENAMIDE COMPOUND AND VANILLOID RECEPTOR 1 (VR1) ACTIVITY INHIBITOR | Japan Tobacco, Inc. (JP) | 2007-04-18 | — | — | EP | claimed |
| US-20060035939-A1 | 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2006-02-16 | — | — | US | claimed |
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20100022523-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20100022523-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20100022523-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1775283-A1 | 3-AMINOBENAMIDE COMPOUND AND VANILLOID RECEPTOR 1 (VR1) ACTIVITY INHIBITOR | Japan Tobacco, Inc. (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-20060035939-A1 | 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022523-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | TRPV1, TRPV6, HVCN1 | KCNQ3 135/4885KCNQ2 162/4885KCNE1 75/4885 |
| US-20060035939-A1 | 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | TRPV1, TRPV6, TRPV3 | KCNQ3 126/4885KCNQ2 153/4885KCNE1 65/4885 |
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | TRPV1, TRPV6, HVCN1 | KCNQ3 149/4885KCNQ2 185/4885KCNE1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.